Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson’s disease

This publication has 45 references indexed in Scilit:

• Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls
  Neurological Sciences, 2002
• In vivo regulation of dopamine and noradrenaline release by α_2A‐adrenoceptors in the mouse prefrontal cortex
  European Journal of Neuroscience, 2002
• The ?2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions ofL-dopa in the MPTP-lesioned primate model of Parkinson's disease
  Movement Disorders, 1999
• Neuroprotective Effects of the α2-Adrenoceptor Antagonists, (+)-Efaroxan and (±)-Idazoxan, against Quinolinic Acid-Induced Lesions of the Rat Striatum
  Experimental Neurology, 1998
• Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
• Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra
  Brain Research, 1994
• 3-O-Methyldopa Attenuates the Effects of Madopar on the Haloperidol-lnduced Cataleptic Behavior and the Locomotor Activity in the Mouse
  Pharmacology, 1994
• A rapid method for the regional dissection of the rat brain
  Pharmacology Biochemistry and Behavior, 1980
• Chronic agonist‐induced hypersensitivity and on‐off hyperkinesis
  Annals of Neurology, 1979
• Amphetamine-induced release of dopamine from the substantia nigra
  Life Sciences, 1976